Valuation: Mesoblast Limited

Market Cap 2.29B 1.6B 1.43B 1.32B 1.2B 2.25B 152B 15.84B 6.22B 79.45B 6.01B 5.88B 254B P/E 2027 *
-74.6x
P/E 2028 * 18.7x
Enterprise Value 2.39B 1.68B 1.49B 1.38B 1.25B 2.36B 159B 16.56B 6.5B 83.06B 6.28B 6.15B 265B EV / Sales 2027 *
9.38x
EV / Sales 2028 * 5.84x
Free-Float
63.88%
Yield 2027 *
-
Yield 2028 * -
1 day-0.56%
1 week-14.56%
Current month-16.59%
1 month-16.59%
3 months-27.87%
6 months-21.78%
Current year-35.29%
1 week 1.74
Extreme 1.735
2.02
1 month 1.74
Extreme 1.735
2.29
Current year 1.74
Extreme 1.735
3.31
1 year 1.74
Extreme 1.735
3.31
3 years 0.26
Extreme 0.255
3.37
5 years 0.26
Extreme 0.255
3.37
10 years 0.26
Extreme 0.255
5.7
Manager TitleAgeSince
Chief Executive Officer 69 2011-03-22
Director of Finance/CFO 59 2025-11-16
Chief Tech/Sci/R&D Officer - 2026-03-10
Director TitleAgeSince
Director/Board Member 69 2006-12-31
Director/Board Member 75 2013-04-14
Director/Board Member 79 2014-03-05
Date Insider Type Main position Quantity % Market Cap. Importance
8/19/26 Free

Director

875,000 0.0674%
7/17/26 Exercice

Founder

1,885,334 0.1456%
7/17/26 Exercice

Founder

-1,885,334 0.1456%
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%-14.56%-32.82%+369.33% 1.61B
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+6.41%+9.61%+73.07% 51.2B
+0.74%+2.15%+30.95%+43.43% 43.76B
+3.87%+9.73%+21.52%+142.33% 42.09B
+7.91%+1.34%+263.31%+577.76% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +2.74%-0.95%+44.33%+145.90% 37.74B
Weighted average by Cap. +3.04%+0.56%+51.33%+123.77%

Financials

2027 *2028 *
Net sales 255M 179M 159M 148M 133M 251M 16.92B 1.77B 694M 8.86B 670M 656M 28.28B 416M 292M 260M 241M 218M 410M 27.64B 2.88B 1.13B 14.47B 1.09B 1.07B 46.18B
Net income -26.28M -18.42M -16.4M -15.21M -13.76M -25.91M -1.74B -182M -71.52M -913M -69.05M -67.61M -2.92B 105M 73.38M 65.33M 60.59M 54.81M 103M 6.95B 725M 285M 3.64B 275M 269M 11.61B
Net Debt 104M 72.96M 64.96M 60.25M 54.5M 103M 6.91B 721M 283M 3.62B 273M 268M 11.55B 143M 100M 89.31M 82.84M 74.93M 141M 9.5B 992M 389M 4.97B 376M 368M 15.88B
Projected Income Statement - Annual - Mesoblast Limited
Logo Mesoblast Limited
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Employees
108
Date Price Change Volume
26-10-20 A$1.775 +0.85% 509,372
26-10-20 A$1.760 -0.56% 4,812,766
26-10-19 A$1.770 -11.06% 10,085,003
26-10-16 A$1.990 +2.58% 16,782,621
26-10-15 A$1.940 -2.51% 3,733,284
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Mesoblast Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.760AUD
Average target price
3.573AUD
Spread / Average Target
+103.03%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Mesoblast Limited